Emerging drugs in peripheral arterial disease

Area of Science:

• Vascular Medicine
• Cardiovascular Research
• Medical Therapeutics

Background:

• Peripheral arterial disease (PAD) results from atherosclerotic blockages in non-coronary arteries, commonly affecting lower extremities and presenting as intermittent claudication or critical limb ischemia.
• PAD signifies widespread atherosclerosis, with 80% of patient mortality linked to cardiovascular events, necessitating a focus on systemic risk reduction.

Purpose of the Study:

• To review the current understanding of Peripheral arterial disease (PAD) management, emphasizing risk reduction and limb-directed therapies.
• To highlight the limitations of existing treatments and the need for novel therapeutic strategies in PAD.

Main Methods:

• Review of current medical literature on Peripheral arterial disease (PAD) pathophysiology, clinical presentation, and management strategies.
• Analysis of existing data on the efficacy of risk reduction and limb-directed therapies for PAD.
• Identification of emerging therapeutic targets and ongoing research in PAD treatment.

Main Results:

• Current PAD management prioritizes cardiovascular risk reduction, with recommendations often extrapolated from coronary and cerebrovascular disease studies.
• Limb-directed therapies offer partial symptom relief and adjunct support for surgical interventions but their effect on disease progression is not fully understood.
• New therapies are being developed to target local disease progression, minimize disability, reduce systemic cardiovascular risk, and enhance surgical outcomes in PAD patients.

Conclusions:

• Peripheral arterial disease (PAD) management requires a dual approach: aggressive systemic risk reduction for cardiovascular protection and targeted therapies for limb salvage and functional improvement.
• Existing non-operative treatments for PAD have limitations, underscoring the critical need for innovative therapies to improve patient outcomes and long-term prognosis.